

CHARLOTTE'S WEB

STANLEY BROTHERS



CRAFTED IN NATURE. PERFECTED BY SCIENCE. TRUSTED BY FAMILIES.

SEPTEMBER 2018

Forward-Looking Information

Certain statements contained in this presentation constitute forward-looking statements and forward-looking information (collectively, “forward-looking statements”). Such forward-looking statements relate to possible events, conditions or financial performance of the Company based on future economic conditions and courses of action. All statements other than statements of historical fact are forward-looking statements. The use of any words or phrases such as “seek”, “anticipate”, “plan”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “predict”, “potential”, “targeting”, “intend”, “could”, “might”, “should”, “believe”, “will likely result”, “are expected to”, “will continue”, “is anticipated”, “believes”, “estimated”, “intends”, “plans”, “projection”, “outlook” and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, assumptions, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. The Company believes there is a reasonable basis for the expectations reflected in the forward-looking statements, however no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this presentation should not be unduly relied upon by investors. The forward-looking statements speak only as of the date of this presentation and are expressly qualified, in their entirety, by this cautionary statement.

In addition, the Company’s assessment of, and targets for, sales of hemp-derived CBD products, expansion of retail locations through which the Company’s products may be sold, expansion of the Company’s distribution channels, including overseas distribution, development of improvements to the Company’s products and related bioavailability technology, the isolation of additional cannabinoid products, annual revenue, and Adjusted EBITDA, are considered forward-looking statements.

The forward-looking statements and other forward-looking information are based on management’s opinions, estimates and assumptions in light of our experience and perception of historical trends, current trends, current conditions and expected future developments, as well as other factors that management currently believes appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates, and assumptions will prove to be correct. For further details on the forward-looking statements included in this presentation, see “Forward-Looking Statements” and “Forward-Looking Statements relating to Growth Strategy.”

All of the forward-looking information contained in this presentation is expressly qualified by the foregoing cautionary statements. Investors should read the entire prospectus and consult their own professional advisors to ascertain and assess the income tax, legal, risk factors and other aspects of their investment in any securities of the Company.

Non-IFRS Measures and Industry Metrics

This presentation makes reference to certain non-IFRS measures including key performance indicators used by management. These measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of our results of operations from management’s perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of the Company’s financial information reported under IFRS. The Company uses non-IFRS measures including “EBITDA” and “Adjusted EBITDA” which may be calculated differently by other companies. These non-IFRS measures and metrics are used to provide investors with supplemental measures of the Company’s operating performance and liquidity and thus highlight trends in its business that may not otherwise be apparent when relying solely on IFRS measures. The Company also believes that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of companies in similar industries. Management also uses non-IFRS measures and metrics, in order to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and forecasts and to determine components of executive compensation. Prospective investors should review the section entitled “Management’s Discussion and Analysis” in the prospectus for a discussion of the use of “EBITDA” and “Adjusted EBITDA” and reconciliations thereof to the most directly comparable IFRS measures.

DISCLAIMERS

Charlotte's Web Holdings Inc. is an entity that currently does, and is expected to continue to derive its revenues from the production and distribution of hemp-based, CBD wellness products in certain states in the United States. All Industrial Hemp produced and sold by Charlotte's Web constitutes Industrial Hemp under the 2014 Farm Bill, as well as the laws of the states in which it produces and sells such Industrial Hemp.

Federal legislation has scheduled all cannabis grown in the United States as a controlled substance, and as a result, the cultivation or sale of hemp for any purpose in the United States without a Schedule I registration with the U.S. Drug Enforcement Agency (the "DEA") is, unless exempted by the 2014 Farm Bill, illegal.

The Company's position is that its activities fall within the relief from federal interference (e.g. by the DEA) provided by Section 7606 of the 2014 Farm Bill. However, the statute does not explicitly state that private businesses, such as the Company, may cultivate or conduct commercial sales of Industrial Hemp or products derived therefrom. Rather, Section 7606 specifically allows for the "growing or cultivation of Industrial Hemp" for the "purposes of research" pursuant to state "pilot programs" conducted by "institutions of higher education and State departments of agriculture". The Company takes the position that its activities nevertheless fall within the ambit of Section 7606(a)(1) based on the following facts, interpretations and assumptions:

- (i) the fact that permissible research activities under Section 7606(a)(1) includes cultivation for the purpose of research conducted under an agricultural pilot program;
- (ii) the fact that Section 7606(b)(1) provides that agricultural pilot programs include pilot programs to study the marketing of Industrial Hemp;
- (iii) the interpretation and assumption that the Licenses (as defined below) provided to the Company by the CDA (as defined below) to cultivate significant quantities of Industrial Hemp are licenses granted in furtherance of "studying the marketing" of Industrial Hemp. In its interpretation, the Company is further assuming that, because hemp was criminalized for nearly a century, significant long-term commercial activities will be required to provide an understanding of the Industrial Hemp industry for the purpose of meeting the goals of the 2014 Farm Bill, and that because state departments of agriculture are not in the business of selling products, they must contract with and/or license private entities to sell products as part of these marketing studies. This is further based on significant discussions between Company and the CDA pursuant to which the Company understands that the Licenses were granted under Colorado's pilot program.
- (iv) the interpretation that the Company's activities (based on the foregoing facts and assumptions) fall within the ambit of Colorado's agricultural pilot program, notwithstanding that the Company is not an "institution of higher education or State department";
- (v) the fact that all of the Company's cultivation operations conducted through third parties in Oregon and Kentucky (which represent all the Company's cultivation operations outside of Colorado) are also licensed by the respective Departments of Agriculture of these states and the assumption that these third parties operate in compliance with such states' pilot programs. This assumption is further evidenced by the fact that these third party operators provide contractual representations to the Company that they are in fact in compliance with state laws relating to cultivation under their respective state pilot programs and that the Company has been provided copies of the applicable Licenses; and
- (vi) the interpretation and assumption that interstate commerce falls fully within U.S. federal jurisdiction and, as a result, marketing and sales of the Company's products to other U.S. states are permitted by the 2014 Farm Bill notwithstanding that such other states may not have implemented a pilot program or that the Company does not directly participate in such states' existing agricultural pilot programs.

However, there are differing interpretations with respect to whether states must explicitly permit the sale of Industrial Hemp and Industrial Hemp products in order to comply with the 2014 Farm Bill or the DEA's Statement of Principles (as defined below). Based on the assumptions set out above, the Company takes the position that such activities comply whether or not the state has an agricultural pilot project in place. Certain other stakeholders such as the DEA may take a narrower interpretation, namely that in the absence of explicit state approval or recognition and/or of an agricultural pilot program, such activities are prohibited. Similarly, some DEA spokespersons have taken the position that the interstate commercial sale of consumable CBD products is outside the scope of the 2014 Farm Bill.

Certain government agencies (such as the DEA and the U.S. Food and Drug Administration (the "FDA")) and certain federal officials have challenged the scope of permissible commercial activity, including the Company's operations. Some DEA representatives, for example, have stated they believe that producers of CBD-based products, including Charlotte's Web, produce and sell their products in violation of the U.S. Controlled Substances Act (the "CSA") and the Federal Food, Drug, and Cosmetic Act (the "FDCA") because the hemp-based products sold by the Company are derived from the Cannabis plant (as defined below). Similarly, the FDA has indicated that Charlotte's Web's marketing activities fall within FDA jurisdiction and, on occasion, have failed to comply with the FDCA.

The FDA has not approved CBD or other individual cannabinoids as drugs, nor has the FDA deemed CBD or other individual cannabinoids permissible for use in dietary supplements, as dietary ingredients or as safe for use in food. The FDA has taken the position that CBD cannot be marketed in a dietary supplement because it has been the subject of investigation as a new drug pursuant to the IND Preclusion (as defined below). The Company believes there are significant arguments against this position in that all conditions of the applicable statute must be met before the IND Preclusion applies. In addition, the FDA is currently challenging whether the Company's products can be sold in the U.S. without FDA approvals which have not yet been obtained. This matter is still in active discussion with the FDA and is unresolved as at the date of the prospectus. The FDCA does not recognize CBD as safe for use in food products. See "*United States Regulatory Matters - FDA Regulation*".

While the Company disagrees with the positions of each of the DEA and the FDA, there is risk that either or both of these agencies could take law enforcement actions against the Company and/or Charlotte's Web. There is also a risk that state or local authorities could take enforcement actions against the Company and/or Charlotte's Web.

Legal barriers applicable to selling hemp and hemp-derived CBD products result from a number of factors, including the fact that hemp and marijuana are both derived from the Cannabis plant, the rapidly changing patchwork of state laws governing hemp and hemp-derived CBD, the position of some DEA representatives that CBD is a controlled substance and the lack of FDA approval for CBD as a lawful food ingredient, food additive or dietary supplement.

Any investment in the Common Shares is speculative due to a variety of factors, including the nature of the Company's business subsequent to Closing. An investment in these securities should only be made by persons who can afford a total loss of their investment. Legislative and regulatory uncertainties, along with difficulties concerning potential enforcement activities by U.S. federal, state and local governments (or discretion exercised thereby), represent significant risks concerning the Company's business activities. These risks include, but are not limited to:

- the DEA's interpretation and application of existing federal laws and rules concerning both those portions of the Cannabis plant exempted from the definition of "marihuana" under the CSA and those varieties provided for as Industrial Hemp (as defined below) pursuant to the 2014 Farm Bill (as defined below);
- the DEA promulgation of its "Establishment of a New Drug Code for Marihuana Extract", and pending litigation related thereto;
- deference to and reliance on the DEA by federal, state and/or local law enforcement and regulatory authorities;
- positions asserted by the FDA concerning products containing derivatives from Industrial Hemp;
- uncertainty surrounding the characterization of cannabinoids as a dietary ingredient by the FDA;
- enforcement activities by state and/or local law enforcement and regulatory authorities under the auspice of individual state law, regardless of any potential conflict thereby with federal law; and
- both the Omnibus Appropriations Law (as defined below) and the 2014 Farm Bill are set to expire on September 30, 2018, unless extended or replaced by a consolidated version of the 2018 Farm Bill (as defined in the prospectus) currently under review by a joint House/Senate conference committee. See "*United States Regulatory Matters - United States Federal Regulation of Industrial Hemp - Development of Current Regulatory Framework - The Hemp Farming Act of 2018.*"

If the Company's operations are found to be in violation of any of such laws or any other governmental regulations, the Company and/or Charlotte's Web may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of the Company's operations or asset seizures, any of which could adversely affect the Company's business and financial results. If the DEA takes action against the Company and/or Charlotte's Web or the CBD industry notwithstanding the regulatory regime surrounding the 2014 Farm Bill, this could have a material adverse effect on the Company's and/or Charlotte's Web's business, financial condition and results of operations including the cessation of operations entirely. Failure to comply with FDA requirements may result in, among other things, injunctions, product withdrawals, recalls, product seizures, fines and criminal prosecutions. The Company's and/or Charlotte's Web's suppliers, service providers and distributors may elect, at any time, to breach or otherwise cease to participate in supply, service or distribution agreements, or other relationships, on which the Company's operations rely. Loss of its suppliers, service providers or distributors would have a material adverse effect on the Company's and/or Charlotte's Web's business and operational results. Historically, Charlotte's Web has sold its products in international jurisdictions and there is the possibility that any such international jurisdiction could determine that Charlotte's Web was not compliant with applicable local regulations. If Charlotte's Web's sales therein were found to be in violation of such international regulations Charlotte's Web and/or the Company may be subject to enforcement actions in such jurisdictions.

Materially all of the Company's assets, liabilities and operations are exposed to U.S. Cannabis-related activities.

See "Risk Factors" in the prospectus for more information about the risks concerning the Company's and Charlotte's Web's business and operations. See "*United States Regulatory Overview - General Overview*", "*United States Federal Regulation of Industrial Hemp - Development of Current Regulatory Framework - Statement of Principles*" and "*United States Federal Regulation of Industrial Hemp - Development of Current Regulatory Framework - DEA Position*" for more information about the position of the enforcement authorities.



BRAND
POWER

PRODUCT
QUALITY

FINANCIAL
STRENGTH

CHARLOTTE IS OUR INSPIRATION

In August 2013, CNN aired a documentary featuring Charlotte Figi, whose well-being had significantly improved after the use of the Stanley brothers' customized extract





THE FUTURE OF HEMP

Founded in 2013

Based in Boulder, Colorado

Over the last decade, the Stanley Brothers and the Company have evolved from the proprietary development of a single industrial hemp strain, to a **market leader** in the production and distribution of innovative **hemp-based, cannabidiol (CBD) wellness products**

CHARLOTTE'S WEB IMPROVING LIFE NATURALLY



12 Liquid products 4 Capsule products 4 Topical Products 2 Canine Products New CBD Isolate

A market leader in the production and distribution of innovative hemp-based, CBD wellness products

Strives to improve customers' lives and meet their demands for stringent product quality, efficacy and consistency

BEST-IN-CLASS INDUSTRIAL HEMP-BASED CBD WELLNESS PRODUCTS

HEMP-BASED CBD GROWN, SOLD AND DISTRIBUTED IN THE UNITED STATES

FEDERAL LEGALIZATION OF HEMP

February 7, 2014

President Obama signs Farm Bill into law

- Defined hemp as Cannabis sativa with less than 0.3% THC
- Delegated the authorization to cultivate to individual states
- Created no restrictions for the sale of hemp across state lines

HEMP AS AN AGRICULTURAL COMMODITY

April 12, 2018

Introduction of the Hemp Farming Act of 2018 (“HFA”)

- Calls for permanent legalization of Industrial Hemp
- Introduced by McConnell (R-KY), co-sponsored by Schumer (D-NY)

CONTINUED FEDERAL SUPPORT

March 23, 2018

President Trump signs Consolidated Appropriations Act

- Reaffirmed the rights of Industrial Hemp producers
- Aligned with the language in the 2015, 2016 and 2017 Appropriations Acts signed by President Obama

PROMISING FUTURE FOR HEMP

June 13, 2018

Senate version of the 2018 Farm Bill

- 20-1 vote in favor by the Senate Agriculture Committee
- The HFA was included in the Senate’s 2018 Farm Bill

INVESTMENT HIGHLIGHTS

LEADING MARKET POSITION in a rapidly growing segment

ESTABLISHED AND TRUSTED Charlotte's Web brand

POSITIVE INDUSTRY TRENDS support continued growth

CONTINUED INNOVATION to expand market leading product portfolio

SCALABLE CULTIVATION AND PRODUCTION platforms

STRONG FINANCIAL PERFORMANCE


EXPERIENCED MANAGEMENT TEAM to lead growth

CHARLOTTE'S WEB IS THE #1 BRAND IN THE HEMP-DERIVED CBD MARKET¹

OUTPACING THE INDUSTRY
WITH REVENUE GROWTH OF

172%

year-over-year²



FAST GROWING CBD
SUPPLEMENTS SEGMENT

55%

CAGR between 2016 and 2021

Vertically integrated business model ensures
high-quality, efficacy and consistency

CULTIVATION

MANUFACTURING

DISTRIBUTION

CULTIVATION:

Advanced technology and customized process

Significant Cultivation Operations

- Company operated farms in Colorado and contract farming in Kentucky and Oregon
- 300 acres of irrigated farmland
- Targeting to produce 250,000 – 350,000 lbs of hemp¹
- Over 10 years of experience in plant cultivation

R&D Process to Achieve Scalability

- Control from seed to cultivation and extraction
- **Genetics:** proprietary plant genetics
- **Planting:** GPS-driven planter for optimal germination
- **Harvesting:** customized machinery and advanced procedures
- **Processing:** state-of-the-art plant drying technology

Hemp Production

All figures shown in lbs



MANUFACTURING:

Current Good Manufacturing Practices (cGMP) Certified

In-House Production

- 40,000 ft² manufacturing and R&D facility
- Proprietary Extraction and Isolation Processes¹
- CO₂ Extraction and Alcohol Extraction capability
- Active pharmaceutical ingredient production in-house

Rigid Quality Management

- Tested in-house and by major independent third-party laboratories
- Ability to qualify raw materials and extracts grown or extracted by outside suppliers allowing the company to scale

Packaging and Fulfillment

- Products are packaged at in-house production facility² and shipped via third-party logistics

(1) Patents applied

(2) Third-party manufacturer packages select products



DISTRIBUTION:

Sold across the United States

Direct to consumer via cwhemp.com

- E-commerce sales growth of 60%⁽¹⁾
- 64% of revenue in FY2017

Sold through 2,700 retail locations

- Approximately 3,000 by year-end 2018
- 36% of revenue in FY2017

Expanding distribution channels

- National grocery, drug, mass market, pet and natural/specialty retailers



COMMITMENT TO CONTINUOUS PRODUCT INNOVATION

Our future includes:

- Improved liquid delivery system to enhance efficacy, convenience and frequency of use (i.e. single serve applications, precise dosing mechanisms)
- Botanical blends targeting consumer need states (i.e. sleep and cognitive function)
- Upgraded bioavailability technology (i.e. unique processing of liquid products)
- Additional isolated cannabinoid products (i.e. isolated CBD and CBN)


STRONG FINANCIAL PERFORMANCE

All figures shown in millions, US\$


Revenue and Growth



Gross Profit and Margin



Adjusted EBITDA and Margin¹



(1) Adjusted EBITDA is not recognized measures under International Financial Reporting Standards ("IFRS")

GROWTH PLAN

Building Brand Awareness

Through media events, social platforms, subject experts, legislative participation, public speaking and endorsements

Growth from the Existing Product Portfolio Through Marketing Initiatives

Introducing integrated marketing efforts that are informed by customer data and leverage multiple platforms, including broader distribution channels

Introduction of New, Differentiated Botanical Products

Tinctures, capsules, powders, sports performance products, topical/cosmetic products, infused beverages and hemp-infused pet products

International Expansion

Global distribution, through partnerships or foreign licensed subsidiaries, with near-term focus on the European Union, South America and Asia

Improved Distribution

Future distribution channels are planned to include national retailers (including grocers and drug chains), vitamin and supplement retailers and natural food stores

Acquisition of Strategic Complementary Companies

Selectively pursue compelling acquisitions that leverage and complement CWB's strengths and meet specific acquisition criteria



SELECT BALANCE SHEET INFORMATION

All figures shown in millions, US\$

JUNE 30th 2018

DECEMBER 31st 2017

CASH	\$10.8	\$7.1
WORKING CAPITAL	\$14.4	\$8.1
TOTAL ASSETS	\$27.6	\$19.5
TOTAL LIABILITIES	\$7.7	\$6.8
SHAREHOLDER'S EQUITY	\$19.8	\$12.6



USE OF PROCEEDS

All figures shown in millions

Expansion of production capacity	US\$20.0
Cultivation infrastructure	US\$14.0
Research and product development	US\$5.0
International expansions	US\$10.0
Working capital, marketing and general corporate purposes	US\$22.5
Total	US\$71.5

2018 AND 2019 FINANCIAL TARGET ESTIMATES

All figures shown in millions, US\$

2018 Total annual revenue of \$65 to \$80 million; an increase of \$25 to \$40 million over 2017

Total annual Adjusted EBITDA of \$23 to \$30 million; an increase from \$14.1 million in 2017

Adjusted EBITDA as a percent of revenue of 35% to 37%

2019 Total annual revenue of \$120 to \$170 million

Adjusted EBITDA as a percent of revenue of 35% to 37%



LEADERSHIP TEAM



Hess Moallem
CEO

- Previously, General Counsel for Onnit Labs
- Consumer-packaged goods industry executive and attorney
- Juris Doctor degree from California Western School of Law and Undergraduate Chemistry degree, University of Texas



Rich Mohr
CFO

- Over 25 years of leadership in public and private companies
- MBA from Regis University and a Bachelor's degree in Accounting from Colorado State University.



Mark Kuspa
VP Sales



Jared Stanley
VP Cultivation



Bo Becker
VP Marketing

BOARD OF DIRECTORS

Joel Stanley, Chairman

Former CEO of CWB Holdings, Inc. (“CWB”) and Chairman of Charlotte’s Web Holdings, Inc. since 2013
Co-founded CWB with his six brothers, which was incorporated in December 2013
Leading professional in the cannabis industry, actively educating decision makers at the legislative level

Jared Stanley

Vice President of Cultivation Operations of Charlotte’s Web Holdings, Inc.
Co-founded and served as Director of CWB since its inception in 2013
Degree in Applied Human Sciences from Colorado State University and concentration in Construction Management

Hess Moallem

Previously, General Counsel and CCO for Onnit
Consumer-packaged goods industry executive and attorney
Juris Doctor degree from California Western School of Law & Undergraduate Chemistry degree, University of Texas

John Held

Executive VP, General Counsel and Secretary of Omega Protein Corp.
Founded The Byzantium Group, Red Hawk Industries and American Residential Services
Juris Doctor degree from Cornell Law School & B.A. in Economics and International Relations from Bucknell University

William West

Co-Founded and serves as President of Tesseract Medical Research
Served as Senior Vice President and Global Chief Financial Officer at HID Corporation and co-founded ACRE, LLC
MBA from Harvard Business School & Undergraduate degree from Harvard University

Shane Hoyne

Chief Marketing Officer of Quintessential Brands Group
Previously Chief Marketing Officer Europe of Bacardi Global Brands and was the Senior Brand Director for The Heineken Company
MBA from the University of Strathclyde Business School

Juan Sartori

Chairman and founder of Union Group
Founded UAG, agricultural assets in Uruguay & Latin America
Bachelor’s degree in Business and Economics from École des Hautes Études Commerciales de Lausanne

CAPITALIZATION AND OWNERSHIP


CAPITALIZATION

	JUNE 30, 2018	POST IPO AUG 30, 2018
Basic Shares Outstanding	79.1	92.8
Options & Warrants	13.3	13.8
Fully Diluted Shares Outstanding	91.1	106.5
Cash & Cash Equivalents (US\$M)	11.0	83.1
Total Debt (US\$M)	1.0	1.0

POST-IPO SHARES OUTSTANDING

Treasury Issuance	13,312,150
Secondary & Greenshoe	3,132,850
US Private Placement	802,246
Founders and Pre-IPO Shareholders	75,526,228
Total Shares Outstanding	92,773,474

POST-IPO OWNERSHIP



FOUNDERS AND PRE-IPO SHAREHOLDERS REPRESENT 188,815 (400:1) PROPORTIONAL VOTING SHARES¹

AUGUST 30, 2018 IPO SUMMARY

Issuer	Charlotte’s Web Holdings, Inc. (the “Company”)
Offering	16,445,000 common shares (the “Common Shares”), comprising of 13,312,150 Common Shares from treasury and 3,132,850 Common Shares from the Selling Shareholders including the over-allotment option
Offering Price	C\$7.00 per Common Share
Offering Size	C\$115.1 million
Private Placement	Concurrent non-brokered private placement of 802,246 shares for gross proceeds of up to C\$5,615,722 at the same terms as the Offering
Shares Outstanding Upon Closing	92,773,474 Common Shares
PVS Conversion Rights	Converted to Common Shares at a ratio of 400 Common Shares per Proportionate Voting Share
Lock-Up	180 days for the Company, Directors, Executive Officers and Selling Shareholders
Use of Proceeds	To expand production capacity, cultivation infrastructure, research and product development, international expansion and working capital and general corporate purposes
Jurisdictions	Initial public offering in all provinces of Canada (excluding Quebec) via long form prospectus and into the U.S. via rule 144A
Listing	Canadian Securities Exchange under the symbol “CWEB”
Lead Underwriter	Canaccord Genuity Corp.
Closing Date	August 30, 2018

INVESTMENT HIGHLIGHTS

LEADING MARKET POSITION in a rapidly growing segment

ESTABLISHED AND TRUSTED Charlotte's Web brand


POSITIVE INDUSTRY TRENDS support continued growth

CONTINUED INNOVATION to expand market leading product portfolio

SCALABLE CULTIVATION AND PRODUCTION platforms

STRONG FINANCIAL PERFORMANCE

EXPERIENCED MANAGEMENT TEAM to lead growth



CSE:CWEB

Charlotte's Web Holdings, Inc.

2425 55th Street

Boulder, Colorado

USA

www.cwhemp.com

Cory Pala

Director of Investor Relations

(416) 594-3849

IR@CWhemp.com